Rockefeller Capital Management L.P. - SAREPTA THERAPEUTICS INC ownership

SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 421 filers reported holding SAREPTA THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.00 and the average weighting 0.3%.

Quarter-by-quarter ownership
Rockefeller Capital Management L.P. ownership history of SAREPTA THERAPEUTICS INC
ValueSharesWeighting
Q2 2023$850,426
+149097.5%
8,120
+96.0%
0.00%
+50.0%
Q1 2023$570
+120.1%
4,142
+107.1%
0.00%
+100.0%
Q4 2022$259
-100.0%
2,000
-73.5%
0.00%
-75.0%
Q3 2022$834,000
-23.0%
7,545
-47.8%
0.00%
-33.3%
Q2 2022$1,083,000
-10.1%
14,455
-6.3%
0.01%0.0%
Q1 2022$1,205,000
+0.2%
15,429
+15.4%
0.01%0.0%
Q4 2021$1,203,000
+54.2%
13,367
+58.4%
0.01%
+50.0%
Q3 2021$780,000
+486.5%
8,441
+390.8%
0.00%
+300.0%
Q2 2021$133,000
-0.7%
1,720
-4.5%
0.00%0.0%
Q1 2021$134,000
-51.8%
1,801
+10.2%
0.00%
-50.0%
Q4 2020$278,000
-79.5%
1,635
-83.1%
0.00%
-84.6%
Q3 2020$1,358,000
-18.1%
9,671
-6.6%
0.01%
-23.5%
Q2 2020$1,659,000
+66.2%
10,349
+1.4%
0.02%
+30.8%
Q1 2020$998,000
+324.7%
10,208
+460.0%
0.01%
+333.3%
Q4 2019$235,000
+75.4%
1,823
+2.6%
0.00%
+50.0%
Q3 2019$134,000
-52.5%
1,776
-4.4%
0.00%
-50.0%
Q2 2019$282,000
+27.0%
1,857
-0.6%
0.00%
+33.3%
Q1 2019$222,000
+9.4%
1,868
+0.6%
0.00%
-25.0%
Q4 2018$203,000
-32.3%
1,8570.0%0.00%
-20.0%
Q3 2018$300,000
+85.2%
1,857
+51.6%
0.01%
+66.7%
Q2 2018$162,0001,2250.00%
Other shareholders
SAREPTA THERAPEUTICS INC shareholders Q1 2023
NameSharesValueWeighting ↓
Perceptive Advisors 2,878,979$69,182,0007.27%
Eventide Asset Management 259,100$6,226,0000.97%
GLADE BROOK CAPITAL PARTNERS LLC 251,000$6,032,0000.93%
IMS Capital Management 32,215$774,0000.91%
Perceptive Advisors 350,000$8,413,0000.88%
Benchmark Capital Advisors 34,900$839,0000.58%
BECK CAPITAL MANAGEMENT, LLC 24,744$636,0000.49%
SABBY MANAGEMENT, LLC 352,100$8,461,0000.47%
Hatteras Alternative Mutual Funds, LLC 39,404$947,0000.46%
Potomac Capital Management, Inc. 22,100$531,0000.45%
View complete list of SAREPTA THERAPEUTICS INC shareholders